Biopharmaceuticals: Recent approvals and likely directions

Trends in Biotechnology

Volumn 23, Issue 11, 2005, Pages 553-558

  Walsh, Gary ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; MARKETING; MEDICAL APPLICATIONS; NUCLEIC ACIDS; PROTEINS;

ALTERNATIVE PRODUCTION SYSTEMS; BIOPHARMACEUTICALS; NUCLEIC-ACID BASED PRODUCTS;

BIOMEDICAL ENGINEERING;

ADALIMUMAB; ANTIANEMIC AGENT; ANTIBODY; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; ANTITHROMBIN; APTAMER; ASPARAGINASE; BETA1A INTERFERON; BEVACIZUMAB; BLOOD CLOTTING FACTOR 8; CETUXIMAB; CHOLERA VACCINE; EFALIZUMAB; EPRIX; ETANERCEPT; FANOLESOMAB TC 99M; FOMIVIRSEN; GENDICINE; HUMAN INSULIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; NUCLEIC ACID; OBLIMERSEN; PALIFERMIN; PEGAPTANIB; PEGINTERFERON; PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HEPATITIS B VACCINE; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CHOLERA; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DENTAL CARIES; DIABETES MELLITUS; DRUG APPROVAL; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; EUROPE; GENE DELIVERY SYSTEM; HEAD AND NECK CANCER; HUMAN; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PSORIASIS VULGARIS; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SACCHAROMYCES CEREVISIAE; STREPTOCOCCUS MUTANS; TRANSGENIC ANIMAL; TRANSGENIC PLANT; UNITED STATES;

BIOPHARMACEUTICS; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; EUROPE; FORECASTING; NUCLEIC ACIDS; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS; UNITED STATES;

EID: 26944499416     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2005.07.005     Document Type: Review

References (36)

1. G. Walsh Biopharmaceuticals, Biochemistry and Biotechnology 2nd edn 2003 John Wiley & Sons
2. G. Walsh Biopharmaceutical benchmarks - 2003 Nat. Biotechnol. 21 2003 865 870
3. J.M. Reichert, and C. Paquette Therapeutic recombinant proteins: trends in US approvals 1982-2002 Curr. Opin. Mol. Ther. 5 2003 139 147
4. G. Walsh Biopharmaceutical benchmarks Nat. Biotechnol. 18 2000 831 833
5. N. Katre The conjugation of proteins with polyethylene glycol and other polymers - altering properties of proteins to enhance their therapeutic potential Adv. Drug Del. Rev. 10 1993 91 114
6. Anonymous Diabetes Action Report 2004 World Health Organization (http://www.who.int )
7. T. Kjeldsen Yeast secretory expression of insulin precursors Appl. Microbiol. Biotechnol. 54 2000 277 286
8. G. Walsh Therapeutic insulins and their large-scale manufacture Appl. Microbiol. Biotechnol. 67 2005 151 159
9. R. Chance Insulin Lispro (Humalog) G. Walsh B. Murphy Biopharmaceuticals, an Industrial Perspective 1999 Kluwer Academic Publications 149 171
10. K. McKeage, and K.L. Goa Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus Drugs 61 2001 1599 1624
11. D.R. Owens, and S. Griffiths Insulin glargine (Lantus) Int. J. Clin. Pract. 56 2002 460 466
12. S. Havelund The mechanism of protraction of insulin detemir, a long acting acylated analogue of human insulin Pharm. Res. 21 2004 1498 1504
13. T. Chapman Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus Drugs 64 2004 2577 2595
14. Anonymous Biotechnology Medicines in Development 2004 PhRMA (http://www.phrma.org )
15. F.M. Wurm Production of recombinant protein therapeutics in cultivated mammalian cells Nat. Biotechnol. 22 2004 1393 1398
16. F. Baneyx, and M. Mujacic Recombinant protein folding and misfolding in Eschericia coli Nat. Biotechnol. 22 2004 1399 1407
17. T.U. Gerngross Advances in the production of human therapeutic proteins in yeasts and filamentous fungi Nat. Biotechnol. 22 2004 1409 1414
18. J. Ma Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans Nat. Med. 4 1998 601 606
19. D.R. Owens Alternative routes of insulin delivery Diabet. Med. 20 2003 886 898
20. J. Patton Mechanisms of macromolecule absorption by the lungs Adv. Drug Del. Rev. 19 1996 3 36
21. K. Powell Inhaled insulin products puff along Nat. Biotechnol. 22 2004 1195 1196
22. T. Blankenstein Gene Therapy: Principles and Applications 1999 Birkhauser-Verlag
23. W.H. Gunzburg Retroviral gene therapy - where now? Trends Mol. Med. 9 2003 277 278
24. Z. Peng The genesis of gendicine: the story behind the first gene therapy Biopharm Int. 17 2004 42 49
25. S.T. Crooke Antisense strategies Curr. Mol. Med. 4 2004 465 487
26. A.M. Denli, and G.J. Hannon RNAi: an ever growing puzzle Trends Biochem. Sci. 28 2003 196 201
27. A. Fire Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
28. G.J. Hannon RNA interference Nature 418 2002 244 251
29. Anonymous RNAi enters trials Nat. Biotechnol. 22 2004 1066
30. S.M. Nimjee Aptamers: an emerging class of therapeutics Annu. Rev. Med. 56 2005 555 583
31. T.S. Sadiq, and D.A. Gerber Stem cells in modern medicine: Reality or myth? J. Surg. Res. 122 2004 280 291
32. E.A. Mayhall The clinical potential of stem cells Curr. Opin. Cell Biol. 16 2004 713 720
33. J.M. Reichert, and A. Pavlov Recombinant protein therapeutics - success rates, market trends and values to 2010 Nat. Biotechnol. 22 2004 1513 1519
34. O.H. Brekke, and G.A. Loset New technologies in therapeutic antibody development Curr. Opin. Pharmacol. 3 2003 544 550
35. G. Walsh Modern antibody-based therapeutics Biopharm. Int. 17 2004 18 25
36. F. Breedveld Therapeutic monoclonal antibodies Lancet 355 2000 735 740